QUOTE AND NEWS
Benzinga  8 hrs ago  Comment 
Legendary investor and co-founder Home Depot Inc (NYSE: HD), Kenneth "Ken" Langone was on this week's edition of Wall Street Week where he discussed his current top-picks: Schlumberger Limited. (NYSE: SLB), Eli Lilly and Co (NYSE: LLY) and...
FierceBiotech  Jun 19  Comment 
Eli Lilly and Teva, racing with a pack of drugmakers with a new approach to treating migraines, said their respective injected therapies succeeded in midstage trials, setting the stage for pivotal studies.
newratings.com  Jun 19  Comment 
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated Cyramza (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma or HCC,...
Benzinga  Jun 18  Comment 
In a report published Thursday, Argus analyst John Eade maintained his Buy rating on Eli Lilly and Co (NYSE: LLY), while raising the target price from $80 to $92. The stock has been witnessing solid momentum in recent weeks, gaining 13.5 percent...
GenEng News  Jun 17  Comment 
Eli Lilly today said it was launching a pair of collaborations with research institutions focused on developing new cancer therapies. The value of both partnerships was undisclosed. Lilly has entered into a strategic partnership with Sarah...
Jutia Group  Jun 17  Comment 
[PR Newswire] - INDIANAPOLIS, June 17, 2015 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint in a Phase 2b...
FierceBiotech  Jun 17  Comment 
Eli Lilly inked a pair of deals with Harvard's Dana-Farber Cancer Institute and the Sarah Cannon Research Institute to hit the gas on oncology R&D, aiming to shorten the development process for a slew of new medicines.
TheStreet.com  Jun 17  Comment 
NEW YORK (TheStreet) -- Eli Lilly & Co. stock coverage was initiated by analysts at Piper Jaffray with an "overweight" rating and a price target of $97."We see Lilly as a compelling pipeline-driven recovery story after the earnings squeeze it...
Market Intelligence Center  Jun 17  Comment 
The patented options-trade picking algorithms used by MarketIntelligenceCenter.com found a trading opportunity with Eli Lilly and Co (LLY) that should provide a 4.26% return in just 65 days. Sell one Aug. '15 call at the $85.00 level for each 100...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki